Using solubel peptide-MHC tetramer, the trial of staining and cloning the melanoma antigen-specific cytotoxic lymphocytes
Using solubel peptide-MHC tetramer, the trial of staining and cloning the melanoma antigen-specific cytotoxic lymphocytes
批准号:
11670849
负责人:
SAKURAI Toshiharu
金额:
$2.43万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1999
资助国家:
日本
项目状态:
已结题
起止时间:
1999 至 2000
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The purpose of this project is to construct the soluble class I MHC-peptide complex ("tetramers") and to visualize the melanoma antigen-specific cytotoxic lymphocytes (CTL) using the produced tetramers.1. We have produced HLA-A2/gp100_<(209-217)>, HLA-A2/MART-1_<(27-35)>, and HLA-A24/EBV-P tetramers. The β2-microglobulin (β2m) and soluble HLA-A2 and A24 heavy chains linked at its carboxyl terminus to a BirA substrate peptide were expressed separately in Escherichia coli. The expressed HLA-A2 or A24-BirA substrate peptide and β2m subunits were refolded together in vitro in the presence of synthetic antigenic peptides, corresponding to the HLA-A2-restricted melanoma-immunogenic epitopes of gp100_<(209-217)> (ITDQVPFSV) and MART-1_<(27-35)> (AAGIGILTV), and HLA-A24 restricted viral-immunogenic epitope of EBV-P (TYGPVFMCL). Folded materials were then subjected to enzymatic biotinylation with BirA enzyme. The HLA-A2 or A24/peptide complexes were purified first on a get filtration column and … More subsequently on a Mono Q ion exchange column. Tetrameric complexes of the biotinylated HLA-A2 or A24/peptide were finally produced by mixing the purified biotinylated heterodimers with Streptavidine-phycoerythrin (PE) conjugates at a molar ratio of 4 : 1.2. The specific binding of the HLA-A2/gp100_<(209-217)> and HLA-A2/MART-1_<(27-35)> tetramers were assessed by staining the relevant peptide-specific tumor-infiltrating T-lymphocytes (TILs), TIL1520 and TIL1235 respectively, and analyzing them on flow cytometry. The HLA-A2/gp100_<(209-217)> tetramer specifically stained more than 90% of TIL1520 specific for the gp100_<(209-217)> peptide, but, did not stain TIL1370 specific for irrelevant gp100_<(154-162)> (G154 : KTWGQYWQV) peptide. In addition, using HLA-A24/EBV-P tetramer, we have analyzed EBV-P specific CTL that was generated by in vitro stimulation with the peptide from peripheral blood mononuclear cells (PBMCs) of HLA-A24 healthy donor and the CTL were found to stain with the tetramer.These results indicate that the produced peptide-MHC tetramers can be used to specifically bind to antigen-specific CTL restricted by both HLA-A2 and HLA-A24, and possibly to enrich specific CTL among a heterogeneous population. Less
期刊论文(16)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
YUTAKA KAWAKAMI: "Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma"Journal of Immunotherapy. 23. 17-27 (2000)
YUTAKA KAWAKAMI:“来自 123 名黑色素瘤患者的肿瘤浸润 T 淋巴细胞对与主要 HLA-A 等位基因相关的共有黑色素瘤抗原的识别”《免疫治疗杂志》。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Y.Kawakami, X.Wang, T.Shofuda, H.Suminoto, J.P.Tupesis, E.Fitzgerald, and S.A.Rosenberg.: "Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor infiltrating T lymphocytes."J Immunology. 166. 2871-2877 (2
Y.Kawakami、X.Wang、T.Shofuda、H.Suminoto、J.P.Tupesis、E.Fitzgerald 和 S.A.Rosenberg.:“分离出一种新的黑色素瘤抗原 MART-2,其中含有可被自体肿瘤浸润 T 识别的突变表位
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Kawakami, Y.: "Development of new immunotherapy using cancer antigens recognized by Tlymphocytes."New Strategy for Cancer Treatment, Proceedings of the 3rd Shizuoka Forum on Health and Longevity. 62-68 (2000)
Kawakami, Y.:“利用 T 淋巴细胞识别的癌症抗原开发新的免疫疗法。”癌症治疗新策略,第三届静冈健康与长寿论坛论文集。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Coulie PG: "Antitumor immunity at work in a melanoma"Advances in Cancer Research. 76. 213-242 (1999)
Coulie PG:“抗肿瘤免疫在黑色素瘤中发挥作用”癌症研究进展。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
YUTAKA KAWAKAMI: "Identification of human melanoma antigens recognized by tumor infiltrating T lymphocytes and their use for immunotherapy"Gann Monograph on Cancer Research. 48. 179-189 (1999)
YUTAKA KAWAKAMI:“肿瘤浸润 T 淋巴细胞识别的人类黑色素瘤抗原的鉴定及其在免疫治疗中的应用”江恩癌症研究专着。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 14 条
Molecular link between stress response and cancer and its clinical implication
-
批准号:17K09396
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.0万
-
财政年份:2017
-
负责人:SAKURAI Toshiharu
-
依托单位:
Novel molecular target in colorectal cancer and inflammatory bowel disease
-
批准号:26460979
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.08万
-
财政年份:2014
-
负责人:SAKURAI Toshiharu
-
依托单位:
Translational research focusing on the regulation of proteasome by Gankyrin
-
批准号:23590998
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.33万
-
财政年份:2011
-
负责人:SAKURAI Toshiharu
-
依托单位:
Elucidation of the resistance mechanisms of immunotherapy by the abnormal signal transduction in melanoma and development of methods to overcome it
-
批准号:21591445
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.91万
-
财政年份:2009
-
负责人:SAKURAI Toshiharu
-
依托单位:
The study of immunosuppressive mechanisms induced by gastrointestinal cancer during epithelial-mesnchymal transition and clinical application of this target therapy
-
批准号:18591484
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.57万
-
财政年份:2006
-
负责人:SAKURAI Toshiharu
-
依托单位:
Identification of novel autoantigens using human IgG in SCID mice implanted with lacrimal and salivary grands from patients with Sjogren's Syndrome
-
批准号:16590324
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.3万
-
财政年份:2004
-
负责人:SAKURAI Toshiharu
-
依托单位:
Using soluble HLA-peptide tetramer, the studies on the cloning and immune-response monitoring of melanoma antigen-specific cytotoxic lymphocyte
-
批准号:13670901
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.3万
-
财政年份:2001
-
负责人:SAKURAI Toshiharu
-
依托单位:
Development and Characterization of Desmoglein-3 Specific T cells from Japanese Patients with Pemphigus Vulgaris
-
批准号:10670804
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.43万
-
财政年份:1998
-
负责人:SAKURAI Toshiharu
-
依托单位:
国内基金
海外基金
登录
查看更多内容
特异识别ALDH1A1的HLA-A2限制性CTL 联合SHH抑制剂杀伤胰腺癌干细胞的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2022
-
负责人:蔡磊
-
依托单位:
HLA-A2抗体通过Src-钙信号通路诱发TRALI的作用及相关机制研究
-
批准号:81760381
-
项目类别:地区科学基金项目
-
资助金额:32.0万元
-
批准年份:2017
-
负责人:乐爱平
-
依托单位:
HLA-A2限制性食管癌特异性突变抗原CTL新表位的鉴定和免疫活性研究
-
批准号:81601448
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:吴亚红
-
依托单位:
汉滩病毒糖蛋白HLA-A2限制性CTL表位免疫保护性作用的评价
-
批准号:81401297
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2014
-
负责人:马樱
-
依托单位:
卵巢癌相关抗原TM4SF1 HLA-A2限制性CTL表位的预测、筛选及免疫反应性鉴定
-
批准号:81360387
-
项目类别:地区科学基金项目
-
资助金额:50.0万元
-
批准年份:2013
-
负责人:阳志军
-
依托单位:
维吾尔族霍奇金淋巴瘤EBV-LMP2A多肽激发的HLA-A2限制性CTL应答研究
-
批准号:81060190
-
项目类别:地区科学基金项目
-
资助金额:24.0万元
-
批准年份:2010
-
负责人:李迅
-
依托单位:
中国人群常见HLA-A2亚型之间抗原特异性差异的实验研究
-
批准号:30901320
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2009
-
负责人:陆盛军
-
依托单位:
乳腺癌PIWIL2、PLAC1抗原HLA-A2限制性CTL表位鉴定以及综合改造策略研究
-
批准号:30901362
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2009
-
负责人:高艳锋
-
依托单位:
鉴定PAX2蛋白中可诱导抗肿瘤CTL免疫的HLA-A2限制性表位
-
批准号:30700986
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2007
-
负责人:解丽华
-
依托单位: